MYGNMyriad Genetics, Inc.
$5.83-26% 1Y
$5.83
$2.8752 weeks$8.18
MYGN in its own filings
MYGN's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
444
Events found in the filings · across 2,064 filings · the record starts in 1996
- Hard flags
- 2
Hard flags
- Most recent filing
- Oct 20, 2026
Most recent filing · Form 8-K
- Record starts
- Oct 15, 1996
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 2, 2026
- Change in certifying accountanthistorical
- 2006-09-14
- Late periodic reporthistorical
- 2021-03-02
- Delisting notice / listing-rule failurehistorical
- 2005-03-25
- SEC comment-letter activity20 occurrences
- 2026-03-02
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 20, 2026On October 19, 2026, Myriad Genetics, Inc., a Delaware corporation (the “Company”), and Laboratory Corporation of America, a Delaware corporation (“Buyer”), entered into an Asset Purchase Agreement (the “Purchase Agreement”)Material agreement entered · Form 8-K
- Oct 9, 2026On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Brian Donnelly, the Company’s former Chief Commercial Officer.Director or officer change · Form 8-K
- Sep 16, 2026On September 16, 2026, Myriad Genetics, Inc. (the “Company”) announced that, effective September 16, 2026, Brian Donnelly no longer serves as Chief Commercial Officer of the Company.Director or officer change · Form 8-K
- Jul 30, 2026Myriad Genetics Reports Second Quarter 2026 Financial Results;.Earnings release · press release
- Jun 23, 2026On June 17, 2026, Daniel M. Skovronsky M.D., Ph.D., a member of the Board of Directors of Myriad Genetics, Inc. (the “Company”) notified the Company that he is resigning as a director, effective immediately.Director or officer change · Form 8-K
- Jun 4, 2026, Myriad Genetics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company's stockholders approved an amendment to the Company's Amended and Restated 2012 Employee Stock Purchase Plan (the "Purchase Plan"), to increase the number of shares authorized for issuance …Director or officer change · Form 8-K
- May 5, 2026Myriad Genetics Reports First Quarter 2026 Financial Results;.Earnings release · press release
- Feb 23, 2026Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results;.Earnings release · press release
- Jan 12, 2026Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance.Earnings release · press release
- Nov 4, 2025Myriad Genetics Reports Third Quarter 2025 Financial Results;.Earnings release · press release
- Nov 3, 2025Myriad Genetics Reports Third Quarter 2025 Financial Results;.Earnings release · press release
- Oct 7, 2025On October 1, 2025, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Scott J. Leffler, the Company’s former Chief Financial Officer.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Diagnostics & Research
Ranks #16 of 21 by RyuScore